Fred Hutchinson
Fred Hutchinson Cancer Research Center names new president, director
Fred Hutchinson Cancer Research Center has named Thomas J. Lynch Jr., MD, as its president and director.
Despite lower price of generic imatinib, overall costs for chronic myeloid leukemia remain high
ORLANDO — The price of generic imatinib has decreased substantially in the United States over the past 2 years, according to a speaker at ASH Annual Meeting and Exposition.
Harnessing the gut to improve cancer outcomes
The gut microbiome — made up of more than a trillion microbes, archaea, viruses, phages, yeast, fungi and bacteria in the intestine — has long been linked to a variety of issues across medical disciplines, from mental health to digestion, allergies and immune function.
Melanoma rates decline among US adolescents, young adults
Incidence of invasive melanoma decreased among adolescents and young adults in the United States between 2006 and 2015, according to results of a population-based study published in JAMA Dermatology.
Off-the-shelf natural killer cells safe, clinically active for advanced Merkel cell carcinoma
NATIONAL HARBOR, Md. — Allogeneic activated natural killer cell therapy resulted in some antitumor activity with no serious side effects in patients with metastatic Merkel cell carcinoma, according to the results of a phase 2 study presented at the SITC Annual Meeting.
Hematologists, oncologists elected to National Academy of Medicine
NCI-sponsored clinical trials cost-effective, ‘practice influential’
A study by the NCI-sponsored SWOG Cancer Research Network showed nearly half of the network’s phase 3 clinical trials influenced clinical care guidelines or new drug approvals.
T-cell Responses to Concurrent HIV and Herpesvirus Infections
An observational, prospective cohort study to discover new information about how HIV and herpes viruses interact with the immune system, with a goal of learning more about how T cells in the immune system respond to and fight off long-term (chronic) viruses, in order to improve medical care in the future.
TCR-engineered T Cells in Solid Tumors (ACTengine)
NY-ESO-1 TCR Engineered T Cell and HSC After Melphalan Conditioning Regimen in Treating Participants with Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 1, open-label study evaluating the safety and efficacy of adoptive transfer of autologous NY-ESO-1 CD8-TCR engineered T cells and NY-ESO-1 CD4-TCR engineered hematopoietic stem cells after a myeloablative conditioning regimen, with administration of IL-2 in patients with relapsed or treatment-refractory ovarian, fallopian tube or primary peritoneal cancer.